Clinical Trials Resource Center

Pain (Pediatric)

October 22, 2007

Anesiva issued positive results from a phase III trial of Zingo for the treatment of pain associated with venous access procedures in adults. This randomized, double-blind study enrolled 699 adult subjects in the US. The subjects were treated with Zingo or placebo one to three minutes prior to undergoing intravenous cannulation or venipuncture. The primary endpoint was pain upon needle insertion utilizing the Visual Analog Scale (VAS) for pain. The mean pain score in the Zingo-treated group was significantly lower than in the placebo group (p = 0.003). Based on the results, Anesiva plans to file a sNDA with the FDA in early 2008.

This information does not represent a Lupus Research Institute endorsement of any listed study. It is merely a notice that the study is available. If you are presently under the care of a physician for lupus or other conditions, you should not disrupt your current program without discussing it with your doctor(s). Do not contact the Lupus Research Institute for information on these studies. Only contact the listed numbers. The Lupus Research Institute does not have any jurisdiction over or further involvement with these studies, other than to make people aware that they are being conducted.